Yu CJ - Search Results

1

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Yang JC, et al. Among authors: yu cj. Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452895 Clinical Trial.

2

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T. Pallaud C, et al. Among authors: yu cj. Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2. Lung Cancer. 2014. PMID: 25154982 Clinical Trial.

3

IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.

Lin CY, Yu CJ, Shen CI, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI. Lin CY, et al. Among authors: yu cj. Med Oncol. 2022 Sep 30;39(12):242. doi: 10.1007/s12032-022-01812-x. Med Oncol. 2022. PMID: 36180600

4

Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010.

Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. Chen PY, et al. Among authors: yu cj. J Microbiol Immunol Infect. 2014 Apr;47(2):95-103. doi: 10.1016/j.jmii.2012.08.025. Epub 2012 Oct 11. J Microbiol Immunol Infect. 2014. PMID: 23063082 Free article.

5

CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.

Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI. Lin CY, et al. Among authors: yu cj. Clin Transl Oncol. 2022 Nov;24(11):2120-2135. doi: 10.1007/s12094-022-02881-0. Epub 2022 Aug 2. Clin Transl Oncol. 2022. PMID: 35917055

6

Correction to: CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.

Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI. Lin CY, et al. Among authors: yu cj. Clin Transl Oncol. 2022 Nov;24(11):2251-2253. doi: 10.1007/s12094-022-02928-2. Clin Transl Oncol. 2022. PMID: 36087247 No abstract available.

7

Focal necrotizing Histoplasma capsulatum cervical lymphadenitis without evidence of disseminated disease in an immunocompetent patient.

Yu CJ, Yu BV, Bess DW, Yu VY. Yu CJ, et al. Radiol Case Rep. 2024 Oct 30;20(1):361-365. doi: 10.1016/j.radcr.2024.09.154. eCollection 2025 Jan. Radiol Case Rep. 2024. PMID: 39525912 Free PMC article.

8

Molecular Mechanisms of Kaposi Sarcoma-Associated Herpesvirus (HHV8)-Related Lymphomagenesis.

Yu CJ, Damania B. Yu CJ, et al. Cancers (Basel). 2024 Oct 31;16(21):3693. doi: 10.3390/cancers16213693. Cancers (Basel). 2024. PMID: 39518131 Review.

9

Interfacial properties of a ZnO/PTFE composite from density functional tight-binding simulations.

Ryu C, Ri JG, Kim YS, Rim CH, Kim CI, Yu CJ. Ryu C, et al. Among authors: yu cj. RSC Adv. 2024 Nov 4;14(47):35097-35103. doi: 10.1039/d4ra06790h. eCollection 2024 Oct 29. RSC Adv. 2024. PMID: 39497777 Free PMC article.

10

Atomistic insight into the promising thermoelectric performance of the copper-based ternary phosphide CaCuP.

Jong UG, Ryu C, Hwang JM, Kim SH, Ju IG, Yu CJ. Jong UG, et al. Among authors: yu cj. Chem Commun (Camb). 2024 Nov 12;60(91):13400-13403. doi: 10.1039/d4cc04660a. Chem Commun (Camb). 2024. PMID: 39466331

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,042 results

Search Page

Filters